AUTO-3

Unassigned

New Medicines

Relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) - in young adults and children

Information

Advanced therapy medicinal product (ATMP)
Autolus
Autolus

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes

Category

An autologous, dual targeting CAR-T cell candidate which targets CD19 and CD22 antigens of cancer cells
ALL is the most common cancer in children. Global incidence is about 3 per 100,000 population, with about 3 out of 4 cases occurring in children aged under 6 years [1].
Relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) - in young adults and children
Intravenous infusion

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Information

Advanced therapy medicinal product (ATMP)
Autolus
Autolus

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

An autologous, dual targeting CAR-T cell candidate which targets CD19 and CD22 antigens of cancer cells
The overall annual incidence of DLBCL in Europe is 3.8 per 100,000 but the incidence increases with age and varies considerably across Europe [1].
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Intravenous infusion